8-K: SS Innovations Reports Strong 2024 Growth and Outlines Future Expansion Plans

SS Innovations reports significant milestones in 2024, including a four-fold revenue increase and expansion of its surgical robotic system installations, while projecting continued growth and regulatory approvals in the near future.

Summary

• SS Innovations International, Inc. announced its achievements in 2024 and provided preliminary unaudited revenue and net loss results for the year ended December 31, 2024.
• The company's SSi Mantra surgical robotic system has completed over 3,500 surgeries and is clinically validated to perform more than 100 different types of surgical procedures.
• In 2024, SS Innovations sold 37 SSi Mantra Surgical Robotic Systems and installed another 8 systems on a Pay-Per-Use Lease model, ending the year with 64 installations.
• The company expects to report revenues of just over US$22 million for 2024, an almost four-fold increase over its 2023 revenues.
• Gross margins improved from 12.30% in 2023 to an estimated 36.90% in 2024.
• For the quarter ended March 31, 2025, the company anticipates increasing the number of installations from 64 to 78 and estimates revenues of approximately US$6.4 million, with a gross margin of approximately 45%.
• SS Innovations filed 69 patent applications, was granted 5 utility patents and 30 design patents, and has 53 registered trademarks in 2024.
• The company expects to receive regulatory approvals in the United States and Europe by the end of 2025 or early 2026.
• SS Innovations has performed 16 telesurgeries using its SSi Mantra, including a robotic cardiac surgery over a distance of 2,000km.
• The company unveiled its Mobile Tele-Surgical Unit, a bus housing the SSi Mantra-3 Surgical Robotic System, aimed at improving remote surgical access and healthcare delivery.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improving margins, and expansion into new markets. The company's focus on innovation and accessibility is also encouraging.

Positives

• The company achieved significant revenue growth in 2024, with revenues increasing four-fold compared to 2023.
• Gross margins improved substantially in 2024, indicating increased efficiency and profitability.
• The company is expanding its intellectual property portfolio with numerous patent applications and grants.
• SS Innovations is expanding its market reach with installations in multiple hospitals and countries.
• The company is innovating in telesurgery, demonstrating its technological capabilities and expanding access to surgical care.
• The company has reported zero device-related mortality, injuries, or complications in all surgical robotic procedures.

Risks

• The preliminary unaudited results for 2024 and Q1 2025 are subject to change.
• The company's ability to achieve anticipated revenue results for the first quarter of 2025 is based on estimates.
• The company's ability to secure regulatory approvals in the United States and Europe by the end of 2025 or early 2026 is not guaranteed.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.

Future Outlook

The company anticipates continued growth in installations and revenue, with expectations of securing regulatory approvals in the United States and Europe by the end of 2025 or early 2026.

Management Comments

• Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, stated, 'SS Innovations has built a strong foundation in 2024, laying the groundwork to achieve significant milestones in the years ahead.'
• Dr. Srivastava also stated, 'Looking ahead, were diligently working to secure regulatory approvals in the United States and Europe, which we expect to receive by the end of 2025 or early 2026.'

Industry Context

SS Innovations is operating in the rapidly growing surgical robotics market, competing with established players like Intuitive Surgical. The company's focus on affordability and accessibility could allow it to capture a significant share of the global market, particularly in developing countries.

Comparison to Industry Standards

• Intuitive Surgical, the maker of the da Vinci Surgical System, is the dominant player in the surgical robotics market.
• SS Innovations is trying to compete by offering a more affordable system.
• Globally, the surgical robotics market is expected to continue to grow, driven by technological advancements and increasing demand for minimally invasive procedures.
• SS Innovations' focus on telesurgery aligns with the growing trend of remote healthcare and could provide a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and potential for future profitability.
• Employees: Positive impact due to company expansion and job creation.
• Customers: Positive impact due to increased access to affordable surgical robotic technologies.
• Suppliers: Positive impact due to increased demand for components and services.
• Patients: Positive impact due to increased access to robotic surgery.

Next Steps

• Secure regulatory approvals in the United States and Europe.
• Continue to expand manufacturing and Research & Development capabilities.
• Increase the number of installations of SSi Mantra Surgical Robotic Systems.
• Continue to grow and solidify the worldwide intellectual property portfolio.

Key Dates

Keywords

surgical robotics, SSi Mantra, telesurgery, revenue, gross margin, regulatory approvals, SS Innovations